Virax Biolabs presents plans for 2027 U.S. diagnostic testing launch
VRAX•Virax Biolabs is targeting a 2027 U.S. launch of a laboratory-developed test through a proposed hosted laboratory model, with a potential FDA De Novo submission targeted for 2028. The company reported $5.12 million in cash at September 30, 2026, and exploratory pilot testing reported 88% specificity and 92% positive predictive value.
1. Testing launch plans
Virax Biolabs is targeting a 2027 U.S. launch through a proposed hosted laboratory model, retaining assay ownership and testing revenue rights. A potential FDA De Novo submission is targeted for 2028.
2. Study and finances
Results from a 160-participant UK study are delayed beyond the first quarter of 2027 while analysis awaits assay finalization. Cash totaled $5.12 million at September 30, 2026, and targeted cumulative cost savings are approximately $2.4 million through March 2028. Exploratory pilot testing reported 88% specificity and 92% positive predictive value for post-acute infection syndromes.




